盐酸六氨基-γ-酮戊酸(Hexaminolevulinate Hydrochloride) - 在研适应症：原位癌，膀胱癌，宫颈鳞状上皮内病变_专利_临床

概要

基本信息

药物类型

小分子化药

别名

4-Hexyloxycarbonyl-2-oxobutylammoniumchloride、5-ALA hexylester、5-ALA hexylesther

+ [19]

靶点-

作用机制

光敏剂

治疗领域

肿瘤泌尿生殖系统疾病其他疾病

在研适应症

原位癌膀胱癌宫颈鳞状上皮内病变+ [2]

非在研适应症

宫颈上皮内瘤样病变结肠癌生殖器疾病+ [2]

原研机构

Photocure ASA

在研机构

Trettiosjucorp ABPhotocure ASAAsieris Meditech (Hong Kong) Co Ltd

+ [7]

非在研机构-

最高研发阶段批准上市

首次获批日期

瑞士 (2007-11-06),

膀胱癌

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C11H21NO3

InChIKeyRYQOILLJDKPETL-UHFFFAOYSA-N

CAS号140898-97-1

查看全部结构式(2)

关联

34

项与盐酸六氨基-γ-酮戊酸相关的临床试验

NCT06525571 / Not yet recruiting临床3期IIT

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual disease burden and improving recurrence-free survival. Enhanced visualization with BLC may lead to more accurate resections, potentially decreasing recurrence rates and improving long-term outcomes for bladder cancer patients. Patients will be randomized to either WLC TURBT or BLC TURBT, and outcomes will be measured using standard-of-care testing with cystoscopy and cytology, along with minimal residual disease (MRD) burden evaluation using urine next-generation sequencing.

开始日期2025-01-04

申办/合作机构

The Johns Hopkins University

[+1]

NCT05962541 / Not yet recruiting临床4期IIT

Non-inferiority, Phase IV, Open-label, Randomized Controlled Trial of Vesical Imaging- Reporting and Data System (VI-RADS) Followed by Primary Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) Versus Conventional White-light TURBT Plus Repeated-TURBT (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) Candidate for Second Look and Resection

Background: In European Association of Urology (EAU) Guidelines, the vast majority of non-muscle-invasive bladder cancers (NMIBCs) undergo a primary transurethral resection of the bladder tumor (TURBT) followed by a repeat TURBT (Re-TURBT). The Re-TURBT is recommended due to the possibility of residual bladder cancer but is unnecessary in many cases by constituting overtreatment. Currently, no diagnostic strategy or predictive tools have been implemented to further stratify who does or does not benefit from Re-TURBT. Recently, an MRI-based Vesical Imaging Reporting and Data System (VI-RADS) score has been developed to stage as to the preoperative probability of muscle invasion, which could potentially exclude those who do not require a Re-TURBT when a primary high-quality resection is delivered. As such, performing TURBT with standard white light (WL) cystoscopy is known to miss many bladder tumours, which may be poorly visible, and a technique known as with photodynamic diagnosis (PDD) results in lower residual tumor and lower early intravesical recurrence rates. PDD is performed using violet light to improve the detection of these lesions not easily visible with WL cystoscopy.
Methods/Aims: The investigators propose an Italian, single-center, phase IV, open-label, non-inferiority, randomized controlled trial, in which participants (n=112) who had already received a mpMRI/VI-RADS score, are randomized to receive PDD-TURBT, no Re-TURBT versus standard of care represented by conventional WL-TURBT followed by WL-Re-TURBT. The primary outcome is proportions of early recurrence in the urinary bladder. Secondary outcomes will include proportions of late BCa recurrence, late disease-free interval, time to progression to MIBC, patient's quality of life assessment, and cost-analysis.
Perspective: The CUT-less trial aims to respond to this unmet need through a non-inferiority randomized clinical study potentially shaping the perspective for a paradigm shift towards a more personalized, socially, and economically sustainable updated NMIBC therapeutic pathway.
Implications: The current clinical trial proposal is aiming to achieve a paradigm shift in the oncological and socio-economical management of urothelial malignancies of the urinary bladder. Our first concern is indeed to guarantee a safe and ground-breaking strategy to manage the pathway of such patients in order to guarantee the non-inferior oncologic safety (and possibly superiority) when compared to the current standard of care.
Additionally, if our hypotheses are confirmed, the investigators will be able to significantly relieve these patients from the oncologic burden of an already invasive and arduous bladder cancer care path. Finally, safely avoiding an unnecessary, expensive surgical procedure will bring significant social and economic benefits to the EU healthcare system and possibly worldwide.

开始日期2025-01-01

申办/合作机构-

NCT05600322 / Completed临床3期

A Prospective, Comparative Within Patient Controlled, Multi-center Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer

A study to compare Hexvix Blue light cstoscopy with standard White light cystoscopy in the detection of bladder cancer.

开始日期2022-11-03

申办/合作机构

Photocure ASA

[+2]

100 项与盐酸六氨基-γ-酮戊酸相关的临床结果

登录后查看更多信息

100 项与盐酸六氨基-γ-酮戊酸相关的转化医学

登录后查看更多信息

100 项与盐酸六氨基-γ-酮戊酸相关的专利（医药）

登录后查看更多信息

192

项与盐酸六氨基-γ-酮戊酸相关的文献（医药）

2024-11-01·Photochemistry and Photobiology

Preclinical evaluation of singlet oxygen‐cleavable prodrugs in combination with protoporphyrin IX‐photodynamic therapy in an orthotopic rat model of non‐muscle‐invasive bladder cancer

Article

作者: You, Youngjae ; Foster, Barbara A. ; Rahman, Kazi Md Mahabubur

AbstractPhotodynamic therapy (PDT) initially employed red light, which caused some patients to experience permanent bladder contractions. PDT using the FDA‐approved drug hexaminolevulinate (HAL), which produces protoporphyrin IX (PpIX) in the tumor, showed some promise but has low efficacy in treating non‐muscle‐invasive bladder cancer (NMIBC). We developed singlet oxygen‐activatable prodrugs of two anticancer drugs, paclitaxel and mitomycin C, to enhance the antitumor effect of PpIX‐PDT without producing systemic side effects, by promoting only local release of the active chemotherapeutic agent. Orthotopic NMIBC model was used to compare the efficacy of prodrugs only, PpIX‐PDT, and prodrugs + PpIX‐PDT. 532 nm laser with a total power of 50 mW for 20 min (60 J, single treatment) was used with HAL and prodrugs. Histology and microscopic methods with image analysis were used to evaluate the tumor staging, antitumor efficacy, and local toxicity. Prodrug + PpIX‐PDT produced superior antitumor efficacy than PpIX‐PDT alone with statistical significance. Both PpIX‐PDT alone and combination therapy resulted in mild damage to the bladder epithelium in the normal bladder area with no apparent damage to the muscle layer. Overall, SO‐cleavable prodrugs improved the antitumor efficacy of PpIX‐PDT without causing severe and permanent damage to the bladder muscle layer.

2024-11-01·Photochemistry and Photobiology

Mitochondrial targeting improves the selectivity of singlet‐oxygen cleavable prodrugs in NMIBC treatment

Article

作者: Woo, Sukyung ; Foster, Barbara A. ; Kumbham, Soniya ; You, Youngjae ; Bist, Ganesh ; Rahman, Kazi Md Mahabubur

AbstractMitochondria play an essential role in cancer treatment by providing apoptotic signals. Hexyl aminolevulinate, an FDA‐approved diagnosis for non‐muscle invasive bladder cancer, induces the production of protoporphyrin IX (PpIX) preferentially by mitochondria in cancer cells. Photosensitizer PpIX upon illumination can release active chemotherapy drugs from singlet oxygen‐activatable prodrugs. Prodrugs placed close enough to PpIX formed in mitochondria can improve the antitumor efficiency of PpIX‐PDT. The preferred uptake of prodrugs by cancer cells and tumors can further enhance the selective damage of cancer cells over non‐cancer cells and surrounding normal tissues. Mitochondriotropic prodrugs of anticancer drugs, such as paclitaxel and SN‐38, were synthesized using rhodamine, a mitochondrial‐targeting moiety. In vitro, the mitochondrial targeting helped achieve preferential cellular uptake in cancer cells. In RT112 cells (human bladder cancer cells), intracellular prodrug concentrations were 2–3 times higher than the intracellular prodrug concentrations in BdEC cells (human bladder epithelial cells), after 2 h incubation. In an orthotopic rat bladder tumor model, mitochondria‐targeted prodrugs achieved as much as 34 times higher prodrug diffusion in the tumor area compared to the nontumor bladder area. Overall, mitochondria targeting made prodrugs more effective in targeting cancer cells and tumors over non‐tumor areas, thereby reducing nonspecific toxicity.

2024-10-01·European Urology

Re: Immune Contexture Changes Following Blue Light Cystoscopy with Hexaminolevulinate in Bladder Cancer

Article

作者: Gakis, Georgios

118

项与盐酸六氨基-γ-酮戊酸相关的新闻（医药）

2024-11-13

·药筛

左奥拉西坦上市申请被否，一个时代终结 | 新产品

昨天的NMPA通知件中，第一个是注射用左奥拉西坦上市申请被否。 2013年，南京优科最早申报了临床，2020年开展了一项590人的三期临床，2023年完成，用了三年多时间。 2023年11月，南京优科按2.1类申报上市，到今天申请被否，用了1年时间。 CDE的态度已经明确，对于此类缺少足够疗效证据支持的产品，大门基本关闭。企业还是不要抱侥幸心理，踏踏实实做点真正有效的产品吧！时代变了！相关阅读：正大天晴 1类新药格索雷塞片，江苏华阳比拉斯汀片首仿获批上市 | 新产品这个凝胶贴膏，再次被否了 | 新产品柯菲平凯普拉生新适应症获批，亚虹灌注用盐酸氨酮戊酸己酯获批上市 | 新产品两个热门品种，6个上市申请被团灭 | 新产品第十批国采分享微信群已建，欢迎企业和代理商入群，对接资源，先到先得了。加客服小狐微信，拉你入群！

上市批准临床3期

2024-11-13

·PRNewswire

Photocure ASA: Results for the third quarter of 2024

OSLO, Norway, Nov. 13, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 120.1 million in the third quarter of 2024 (Q3 2023: NOK 107.3 million), and EBITDA of NOK 5.0 million (NOK 3.3 million) for the Company. Photocure reiterates its 2024 financial guidance and continues to expect consolidated product revenue growth of 6% to 9% in constant currency and positive EBITDA excluding business development expenses. "We delivered solid performance in the third quarter, generating 12% Hexvix/Cysview revenue growth and NOK 5.0 million in EBITDA. Year-to-date, we have reported 9% growth in product revenues. Our business segments in North American and Europe both generated positive contributions during the quarter, and we made progress on key initiatives that we are pursuing to accelerate our growth going forward," says Dan Schneider, President & Chief Executive Officer of Photocure. Photocure reported total group revenues of NOK 120.2 million in the third quarter of 2024 (NOK 107.5 million), and EBITDA* of NOK 5.0 million (NOK 3.3 million), driven by revenue growth in North America and Europe. Hexvix/Cysview revenues ended at NOK 120.1 million in the quarter (Q3 2023: NOK 107.3 million). The EBIT was NOK -2.2 million (NOK -3.9 million) and the cash balance at the end of the period was NOK 291.1 million. At the end of the third quarter of 2024, the installed base of rigid BLC systems in the U.S. was 387, up 13% since Q3 2023. This includes 18 mobile towers owned by ForTec Medical. Photocure estimates that 25 flexible BLC towers remain in the U.S. market. Photocure also entered into a strategic agreement with Richard Wolf GmbH to develop and commercialize a next-generation flexible blue light cystoscope based on Richard Wolf's system blue technology with the goal to reintroduce and grow the use of BLC with Cysview/Hexvix in the surveillance setting. "We are also positioning for the future with our Richard Wolf partnership to develop and commercialize a state-of-the-art flexible high-definition blue light system. This partnership is focused on ensuring that physicians and patients have reliable access to high quality BLC equipment in the surveillance setting. The development project is well underway, with the goal to bring a new flexible BLC system to patients globally as soon as possible. Additionally, the Karl Storz' Citizen's Petition to have BLC equipment reclassified in the U.S. from Class 3 to Class 2 is another significant opportunity that we continue to monitor and pro-actively support," Schneider adds. Photocure believes that the benefits of Blue Light Cystoscopy with Hexvix/Cysview offering superior detection and management of bladder cancer will continue to be adopted and become the standard of care. Photocure reiterates its 2024 guidance and continues to expect consolidated product revenue growth of 6% to 9% in constant currency, positive EBITDA excluding business development expenses, and new and upgraded Saphira™ installations in the U.S. in the range of 55 to 70 towers. "With our business continuing to show steady growth, industry trends in our favor, and a number of initiatives underway that can enable Hexvix/Cysview to grow faster, I believe that Photocure is well-positioned to deliver value to patients and our shareholders in the coming quarters," Schneider concludes. Please find the full financial report and presentation enclosed. EBITDA* and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section of the third quarter 2024 financial report on page 23. The quarterly report and presentation will be published at 08:00 CET and will be publicly available at . Dan Schneider, CEO and Erik Dahl, CFO, will host a live webcast at 14:00 CET. The presentation will be held in English and questions can be submitted throughout the event. The streaming event is available through The presentation is scheduled to conclude at 14:45 CET. For further information, please contact: Dan Schneider President and CEO Photocure ASA Email: [email protected] Erik Dahl Chief Financial Officer Email: [email protected] David Moskowitz Vice President of Investor Relations Tel: +1 202 280 0888 Email: [email protected] Media and IR enquiries: Geir Bjørlo Corporate Communications (Norway) Tel: +47 91540000 Email: [email protected] About Photocure ASA Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at , , All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA. This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Tolv Hillestad, Group Controller, Photocure ASA, on 13 November 2024 at 08:00 CET. This information was brought to you by Cision The following files are available for download: SOURCE Photocure WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

财报

2024-11-12

·亚虹医药

亚虹医药2024 IPVC首次公布其非手术治疗宫颈HSIL产品APL-1702关于不同HPV型别、不同随访时间的HPV清除率数据

中国上海，2024年11月12日 –专注于泌尿生殖系统肿瘤的全球化创新药公司亚虹医药（股票代码：688176.SH）近日宣布，其用于治疗宫颈高级别鳞状上皮内病变（High-Grade Squamous Intraepithelial Lesion, HSIL）产品APL-1702的国际多中心Ⅲ期临床试验结果入选2024年国际乳头瘤病毒大会（International Papillomavirus Conference ,IPVC），并以壁报形式发布本研究关于不同HPV型别、不同随访时间的HPV清除率分析数据。该研究是一项前瞻、随机、双盲、安慰剂对照的国际多中心Ⅲ期临床试验。该试验已达到主要疗效终点，安全性良好。本研究发现APL-1702组在第6个月时基线HPV总体清除率、HPV16/18清除率均明显优于安慰剂组，具体如下：在第3个月、6个月时，APL-1702组中不同型别亚组HPV阳性率均低于安慰剂组，提示APL-1702组HPV转阴速度更快，且在治疗后12个月时HPV转阴仍在持续中。具体如下方森林图所示： APL-1702的新药上市申请于2024年5月获得国家药品监督管理局（NMPA）受理。公司正在积极推进该产品的上市审评审批工作。关于亚虹医药亚虹医药（股票代码：688176.SH）成立于2010年3月，是一家专注于泌尿生殖系统肿瘤及其它重大疾病领域的全球化创新药公司。秉承“改善人类健康，让生命更有尊严”的企业使命，亚虹医药立志成为在专注治疗领域集研发、生产和商业化为一体的国际领先制药企业，为中国和全球患者提供最佳的诊疗一体化解决方案。公司坚持以创新技术和产品为核心驱动力，通过打造自有的研发平台和核心技术，深入探索药物作用机理，高效率筛选评价候选药物。通过内部完善的研发体系和全球药物开发经验专长，亚虹医药致力于在专注治疗领域推出全球首创（First-in-Class）药物和其它存在巨大未被满足治疗需求的创新药物。同时，亚虹医药通过自主研发和战略合作，围绕泌尿生殖系统疾病进行产品管线的深度布局，高度关注该领域的技术前沿和治疗发展趋势，洞察并挖掘未被满足的临床需求，前瞻性地进行产品规划和生命周期管理，打造涵盖疾病诊断到治疗的优势产品组合，从而造福更多的中国和全球患者。欲了解更多信息，请访问www.asieris.cn。

临床3期

100 项与盐酸六氨基-γ-酮戊酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04436	-	V04CX	DB06261

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
原位癌	美国	Photocure ASA	2018-02-15
膀胱癌	瑞士	Ipsen SA	2007-11-06

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
宫颈鳞状上皮内病变	申请上市	中国	Trettiosjucorp AB	2024-05-11
宫颈鳞状上皮内病变	申请上市	中国	Asieris Meditech (Hong Kong) Co Ltd	2024-05-11
宫颈鳞状上皮内病变	申请上市	中国	江苏亚虹医药科技股份有限公司	2024-05-11
膀胱癌	申请上市	中国	Patheon Italia SpA	2023-11-29
膀胱癌	申请上市	中国	Photocure ASA	2023-11-29
膀胱癌	申请上市	中国	Fresenius Kabi Austria GmbH	2023-11-29
鳞状上皮内病变	临床3期	中国	上海亚虹医药科技有限公司	2020-10-20
生殖器疾病	药物发现	挪威	Photocure ASA	2011-08-01
妇科疾病	药物发现	挪威	Photocure ASA	2011-08-01
非肌层浸润性膀胱肿瘤	药物发现	丹麦	Photocure ASA	2005-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04484415 (NEWS) 人工标引	临床3期	宫颈鳞状上皮内病变	-	APL-1702	(顧獵壓鹹夢構製廠範鑰) = 製餘憲鹽願鹹夢壓簾餘繭夢簾壓顧壓網觸構願 (餘製衊衊衊憲積夢顧膚 ) 更多	积极	2024-11-12
				Placebo	(顧獵壓鹹夢構製廠範鑰) = 鏇鹽糧廠淵鏇顧齋艱製繭夢簾壓顧壓網觸構願 (餘製衊衊衊憲積夢顧膚 ) 更多
NCT05600322 (CTgov)	临床3期	膀胱癌	158	Richard Wolf Photodynamic Diagnostic Equipment (PDD) system+Hexaminolevulinate Hydrochloride	鏇壓範繭遞襯蓋繭構膚(艱憲範鑰醖窪壓築遞積) = 繭襯齋醖鹹淵觸簾觸壓遞餘餘範願願齋構觸範 (衊簾蓋醖築觸鹽憲膚廠, 鑰廠襯蓋顧夢糧築簾憲 ~ 醖觸艱願憲廠網鬱積繭) 更多	-	2024-10-03
Company_Website 人工标引	临床3期	宫颈鳞状上皮内病变	-	APL-1702 (Age ≥20 and <30)	遞糧蓋糧齋積獵簾觸齋(廠積齋鑰鬱簾觸構選顧) = 壓蓋醖壓憲淵糧範襯積淵製蓋選繭顧積遞餘繭 (憲艱繭願壓遞鑰積選築 ) 更多	积极	2024-09-29
				PBO (Age ≥20 and <30)	遞糧蓋糧齋積獵簾觸齋(廠積齋鑰鬱簾觸構選顧) = 選廠願鹹廠製製範選範淵製蓋選繭顧積遞餘繭 (憲艱繭願壓遞鑰積選築 ) 更多
Company_Website 人工标引	临床3期	宫颈鳞状上皮内病变	-	APL-1702	(製築觸鑰選壓遞遞鏇醖) = 鏇選壓鹹艱廠積願築憲簾積衊鬱衊遞選築艱鏇 (餘獵蓋壓簾網蓋簾願網 ) 更多	积极	2024-09-17
				Placebo	(製築觸鑰選壓遞遞鏇醖) = 壓願鑰範憲窪顧鹽鏇鹽簾積衊鬱衊遞選築艱鏇 (餘獵蓋壓簾網蓋簾願網 ) 更多
PRNewswire 人工标引	临床3期	鳞状上皮内病变	402	Cevira (APL-1702)	(壓淵鑰鑰觸齋構餘壓鑰) = 網憲餘壓夢獵鑰膚廠範餘積築壓窪鏇鑰蓋構繭 (蓋鬱觸窪鹽鹽願鑰觸襯 ) 更多	积极	2024-03-18
				Placebo	(壓淵鑰鑰觸齋構餘壓鑰) = 簾鹹壓製觸膚顧憲窪廠餘積築壓窪鏇鑰蓋構繭 (蓋鬱觸窪鹽鹽願鑰觸襯 ) 更多
NCT04484415 (APRICITY, Biospace) 人工标引	临床3期	鳞状上皮内病变	402	Cevira (APL-1702)	(鑰觸膚糧鏇鹹網構鏇繭) = 遞壓淵鏇壓蓋糧淵構膚製製觸壓積窪淵鏇製蓋 (選壓繭餘鬱網構繭艱艱 ) 更多	积极	2024-03-18
				Placebo	(鑰觸膚糧鏇鹹網構鏇繭) = 積鹽糧網觸糧願遞鏇鹽製製觸壓積窪淵鏇製蓋 (選壓繭餘鬱網構繭艱艱 ) 更多
NCT03058705 (CTgov)	N/A	膀胱癌	10	Near Infrared Fluorescence (NIRF)+Hexaminolevulinate HCL	衊觸網糧壓積築糧顧範(積遞繭糧餘鹹襯餘選鬱) = 醖鬱遞齋蓋製鏇獵蓋積艱顧鹽醖網遞簾醖顧顧 (範網襯廠窪築顧製觸觸, 簾鹽衊簾夢鏇艱窪齋築 ~ 憲夢範簾築顧夢壓築鹽) 更多	-	2019-08-19
MP43-06 (AUA2019)	N/A	非肌层浸润性膀胱肿瘤	208	Blue light cystoscopy with hexaminolevulinate	夢襯艱壓遞蓋願糧製廠(鏇衊襯範遞願齋憲遞糧) = 衊餘壓鏇糧鏇餘窪衊淵淵壓積鏇淵遞窪淵醖網 (廠餘齋壓餘衊鬱選構鬱 ) 更多	-	2019-04-01
NCT02560584 (CTgov)	临床3期	膀胱癌	304	KARL STORZ D-Light C PDD Flexible Videoscope System+Hexaminolevulinate hydrochloride	鏇網繭艱廠衊鹹製衊餘(願窪艱鹽壓窪憲膚鬱憲) = 鹹繭夢繭遞衊積網艱獵艱膚齋淵醖製鹹鏇繭鹽 (鏇襯築網齋範觸願鹽襯, 襯製顧醖膚築鏇醖製鹹 ~ 膚遞淵顧淵觸範鹽獵鹽) 更多	-	2018-07-02
NCT02560584 \| NCT02660645 (Pubmed \| J Urol)	临床3期	膀胱癌	304	Hexaminolevulinate (Blue light flexible cystoscopy)	鏇構餘齋積鹹遞艱願窪(鹹淵構築衊醖鑰蓋餘淵) = 夢廠鏇觸鹹構鏇願獵構鬱製餘築獵廠鏇蓋廠選 (鑰鹹簾鑰衊糧憲艱衊艱, 17.2 ~ 55.7) 更多	-	2018-05-01
				Hexaminolevulinate (White light flexible cystoscopy)	選願簾繭夢繭遞夢艱願(齋艱膚鑰願壓築範憲艱) = 繭餘繭築醖繭繭淵餘築構醖鹹範憲糧淵糧網鏇 (範構艱衊醖鏇遞蓋顧齋 )